Abingdon Health PLC

Chart & Performance

D1W1MN

P/E

—

P/S

2.20

EPS

—

Div Yield, %

—

Shrs. gr., 5y

25.99%

Rev. gr., 5y

21.92%

Revenues

+51.67%

Net income

-1m

L-63.17%

CFO

-2m

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Abingdon Health Plc develops, manufactures, and distributes diagnostic devices worldwide. It offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; Seralite, a rapid lateral flow test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum; and AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader. The company also provides lateral flow development and manufacturing services. Additionally, it provides consultancy services to businesses in the healthcare technology sector. The company has a collaboration and co-marketing agreement with Abcam plc. Abingdon Health Plc was incorporated in 2008 and is headquartered in York, the United Kingdom.

URL

https://www.abingdonhealth.com/

IPO date

Dec 15, 2020

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title GBP in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title GBP in thousands, except ratios and share amounts	2024‑06	2023‑06	2022‑06	2021‑06	2020‑06	2019‑06	2018‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT